174 related articles for article (PubMed ID: 29377550)
21. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
[TBL] [Abstract][Full Text] [Related]
22. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
[TBL] [Abstract][Full Text] [Related]
23. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR
Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136
[TBL] [Abstract][Full Text] [Related]
24. Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation.
Diez H; Benitez MJ; Fernandez S; Torres-Aleman I; Garrido JJ; Wandosell F
Biochim Biophys Acta; 2016 Nov; 1863(11):2574-2583. PubMed ID: 27421985
[TBL] [Abstract][Full Text] [Related]
25. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
26. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
[TBL] [Abstract][Full Text] [Related]
27. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Kong D; Dan S; Yamazaki K; Yamori T
Eur J Cancer; 2010 Apr; 46(6):1111-21. PubMed ID: 20129775
[TBL] [Abstract][Full Text] [Related]
28. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.
Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A
Cancer Immunol Immunother; 2018 May; 67(5):815-824. PubMed ID: 29487979
[TBL] [Abstract][Full Text] [Related]
29. Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo.
Jonchere B; Williams J; Zindy F; Liu J; Robinson S; Farmer DM; Min J; Yang L; Stripay JL; Wang Y; Freeman BB; Yu J; Shelat AA; Rankovic Z; Roussel MF
Mol Cancer Ther; 2023 Jan; 22(1):37-51. PubMed ID: 36318650
[TBL] [Abstract][Full Text] [Related]
30. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
31. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
Morelli MB; Amantini C; Nabissi M; Cardinali C; Santoni M; Bernardini G; Santoni A; Santoni G
Oncotarget; 2017 Jan; 8(2):3380-3395. PubMed ID: 27926485
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Liu S; Tang Y; Yan M; Jiang W
Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
[TBL] [Abstract][Full Text] [Related]
34. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
[TBL] [Abstract][Full Text] [Related]
36. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
37. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Zheng J; Wang H; Yao J; Zou X
Pharmazie; 2014 Jan; 69(1):38-42. PubMed ID: 24601221
[TBL] [Abstract][Full Text] [Related]
38. JPO2/CDCA7L and LEDGF/p75 Are Novel Mediators of PI3K/AKT Signaling and Aggressive Phenotypes in Medulloblastoma.
Chan TS; Hawkins C; Krieger JR; McGlade CJ; Huang A
Cancer Res; 2016 May; 76(9):2802-12. PubMed ID: 27013196
[TBL] [Abstract][Full Text] [Related]
39. Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma.
Faria CC; Agnihotri S; Mack SC; Golbourn BJ; Diaz RJ; Olsen S; Bryant M; Bebenek M; Wang X; Bertrand KC; Kushida M; Head R; Clark I; Dirks P; Smith CA; Taylor MD; Rutka JT
Oncotarget; 2015 Aug; 6(25):21718-29. PubMed ID: 26061748
[TBL] [Abstract][Full Text] [Related]
40. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
